The chemotherapy of onchocerciasis XVIII. Aspects of treatment with suramin.
We report the clinical and parasitological effects of a modified treatment regimen for suramin. Twenty adult males received up to 5 g (72.5 to 84.7 mg/kg) of suramin over 36 days. Detailed clinical and laboratory examinations were done before treatment and then at intervals over 2 years. Nodules were removed at 6, 13, 26 and 52 weeks for histology. Systemic tolerance was good. Anterior segment inflammation was however common and 2 patients required intervention to prevent posterior synechiae. No new posterior segment lesions developed; a rare improvement occurred in one patient with papillitis. Proteinuria, mostly mild, occurred in nearly all patients. Previously unreported renal glycosuria was documented in one patient. Microfilariae in the skin and anterior chamber did not change significantly for 5 or more weeks after which rapid reductions occurred. Ocular parasites were absent at 2 years and skin microfilariae were near zero. Peripheral blood eosinophil counts fell in parallel with those of microfilariae in the skin and anterior chamber and were normal at one and two years. These findings at 2 years may provide indirect evidence of a macrofilaricidal or a permanent chemosterilant effect on the adult worms. Nodule examination revealed an embryotoxic effect from week 6, a lethal effect on the male worms from month 3 and on the female worms from month 6 after treatment started. At one year 34% of the female worms examined were alive. Thus total doses of suramin in the range 72.5 to 84.7 mg/kg have only a modest lethal effect on the female worms. Suramin remains a restricted drug and a suitable replacement is urgently needed.
Awadzi
K
K
Onchocerciasis Chemotherapy Research Centre (OCRC), Hohoe, Ghana.
Hero
M
M
Opoku
N O
NO
Addy
E T
ET
Büttner
D W
DW
Ginger
C D
CD
D000328:Adult; D000818:Animals; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008938:Mitosis; D017181:Onchocerca volvulus / Q000187:drug effects / Q000302:isolation & purification; D009855:Onchocerciasis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009865:Oocytes / Q000166:cytology; D012867:Skin / Q000469:parasitology; D013498:Suramin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D013498:Suramin